Bharati R Dhruva
Examiner (ID: 3913)
Most Active Art Unit | 1632 |
Art Unit(s) | 1632 |
Total Applications | 2 |
Issued Applications | 1 |
Pending Applications | 1 |
Abandoned Applications | 0 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 15766013
[patent_doc_number] => 20200114024
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-16
[patent_title] => COMPOSITION FOR TREATING CANCEROUS CELLS AND A METHOD THEREFOR
[patent_app_type] => utility
[patent_app_number] => 16/594630
[patent_app_country] => US
[patent_app_date] => 2019-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13320
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16594630
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/594630 | COMPOSITION FOR TREATING CANCEROUS CELLS AND A METHOD THEREFOR | Oct 6, 2019 | Abandoned |
Array
(
[id] => 18492393
[patent_doc_number] => 11697804
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-11
[patent_title] => Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy
[patent_app_type] => utility
[patent_app_number] => 16/589647
[patent_app_country] => US
[patent_app_date] => 2019-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 40
[patent_no_of_words] => 21494
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16589647
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/589647 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | Sep 30, 2019 | Issued |
Array
(
[id] => 17412614
[patent_doc_number] => 20220047518
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-17
[patent_title] => PEG LIPIDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/277452
[patent_app_country] => US
[patent_app_date] => 2019-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42861
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -74
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277452
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/277452 | PEG LIPIDS AND USES THEREOF | Sep 18, 2019 | Pending |
Array
(
[id] => 15324693
[patent_doc_number] => 20200002676
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-02
[patent_title] => TRANSGENIC MACROPHAGES, CHIMERIC ANTIGEN RECEPTORS, AND ASSOCIATED METHODS
[patent_app_type] => utility
[patent_app_number] => 16/572368
[patent_app_country] => US
[patent_app_date] => 2019-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18740
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16572368
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/572368 | Transgenic macrophages, chimeric antigen receptors, and associated methods | Sep 15, 2019 | Issued |
Array
(
[id] => 15290831
[patent_doc_number] => 20190388551
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-26
[patent_title] => NUCLEIC ACID CONSTRUCTS AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/543324
[patent_app_country] => US
[patent_app_date] => 2019-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52024
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16543324
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/543324 | Nucleic acid constructs and methods of using the same | Aug 15, 2019 | Issued |
Array
(
[id] => 15143403
[patent_doc_number] => 20190350179
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => PARKINSONS DISEASE MODEL AND METHODS
[patent_app_type] => utility
[patent_app_number] => 16/527446
[patent_app_country] => US
[patent_app_date] => 2019-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23722
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16527446
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/527446 | Parkinson's disease model and methods | Jul 30, 2019 | Issued |
Array
(
[id] => 17520753
[patent_doc_number] => 20220106602
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-07
[patent_title] => NUCLEIC ACID CONSTRUCT
[patent_app_type] => utility
[patent_app_number] => 17/254001
[patent_app_country] => US
[patent_app_date] => 2019-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12146
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17254001
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/254001 | Nucleic acid construct | Jul 30, 2019 | Issued |
Array
(
[id] => 18329235
[patent_doc_number] => 11634463
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-25
[patent_title] => Methods and compositions for treating hemophilia
[patent_app_type] => utility
[patent_app_number] => 16/523328
[patent_app_country] => US
[patent_app_date] => 2019-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 9
[patent_no_of_words] => 22234
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16523328
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/523328 | Methods and compositions for treating hemophilia | Jul 25, 2019 | Issued |
Array
(
[id] => 15451279
[patent_doc_number] => 20200038463
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-06
[patent_title] => METHODS AND COMPOSITIONS OF MMA CONSTRUCTS AND VECTORS
[patent_app_type] => utility
[patent_app_number] => 16/513576
[patent_app_country] => US
[patent_app_date] => 2019-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17119
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16513576
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/513576 | METHODS AND COMPOSITIONS OF MMA CONSTRUCTS AND VECTORS | Jul 15, 2019 | Pending |
Array
(
[id] => 15913019
[patent_doc_number] => 10653731
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2020-05-19
[patent_title] => Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
[patent_app_type] => utility
[patent_app_number] => 16/512051
[patent_app_country] => US
[patent_app_date] => 2019-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 23
[patent_no_of_words] => 16511
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16512051
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/512051 | Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency | Jul 14, 2019 | Issued |
Array
(
[id] => 15557503
[patent_doc_number] => 20200063163
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-27
[patent_title] => Methods, tip assemblies and kits for introducing material into cells
[patent_app_type] => utility
[patent_app_number] => 16/511292
[patent_app_country] => US
[patent_app_date] => 2019-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20846
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16511292
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/511292 | Methods, tip assemblies and kits for introducing material into cells | Jul 14, 2019 | Issued |
Array
(
[id] => 17726596
[patent_doc_number] => 11382961
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-12
[patent_title] => Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of N-acetyl-aspartic acid
[patent_app_type] => utility
[patent_app_number] => 16/508870
[patent_app_country] => US
[patent_app_date] => 2019-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 10
[patent_no_of_words] => 7430
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16508870
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/508870 | Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of N-acetyl-aspartic acid | Jul 10, 2019 | Issued |
Array
(
[id] => 15895275
[patent_doc_number] => 20200147156
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => ONCOLYTIC VIRAL VECTORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/507789
[patent_app_country] => US
[patent_app_date] => 2019-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32291
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16507789
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/507789 | Oncolytic viral vectors and uses thereof | Jul 9, 2019 | Issued |
Array
(
[id] => 16932809
[patent_doc_number] => 20210198698
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => FUSOSOME COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/258316
[patent_app_country] => US
[patent_app_date] => 2019-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 128440
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -48
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17258316
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/258316 | FUSOSOME COMPOSITIONS AND USES THEREOF | Jul 8, 2019 | Pending |
Array
(
[id] => 15020969
[patent_doc_number] => 20190321489
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-24
[patent_title] => LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY
[patent_app_type] => utility
[patent_app_number] => 16/502672
[patent_app_country] => US
[patent_app_date] => 2019-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17826
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16502672
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/502672 | Lipid nanoparticle compositions and methods for mRNA delivery | Jul 2, 2019 | Issued |
Array
(
[id] => 15035685
[patent_doc_number] => 20190328847
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-31
[patent_title] => MATERIALS AND METHODS USEFUL FOR TREATING GLIOBLASTOMA
[patent_app_type] => utility
[patent_app_number] => 16/456424
[patent_app_country] => US
[patent_app_date] => 2019-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12514
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16456424
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/456424 | Materials and methods useful for treating glioblastoma | Jun 27, 2019 | Issued |
Array
(
[id] => 15361027
[patent_doc_number] => 20200016278
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-16
[patent_title] => STABLE GENE TRANSFER TO PROLIFERATING CELLS
[patent_app_type] => utility
[patent_app_number] => 16/450591
[patent_app_country] => US
[patent_app_date] => 2019-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9480
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16450591
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/450591 | Stable gene transfer to proliferating cells | Jun 23, 2019 | Issued |
Array
(
[id] => 17363681
[patent_doc_number] => 11230698
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-01-25
[patent_title] => Cytokine receptor genes and the use thereof to enhance therapy
[patent_app_type] => utility
[patent_app_number] => 16/448208
[patent_app_country] => US
[patent_app_date] => 2019-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 55
[patent_no_of_words] => 12384
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16448208
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/448208 | Cytokine receptor genes and the use thereof to enhance therapy | Jun 20, 2019 | Issued |
Array
(
[id] => 17052528
[patent_doc_number] => 20210261962
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => CORRECTION OF DYSTROPHIN EXON 43, EXON 45, OR EXON 52 DELETIONS IN DUCHENNE MUSCULAR DYSTROPHY
[patent_app_type] => utility
[patent_app_number] => 17/253606
[patent_app_country] => US
[patent_app_date] => 2019-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29392
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -143
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253606
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/253606 | CORRECTION OF DYSTROPHIN EXON 43, EXON 45, OR EXON 52 DELETIONS IN DUCHENNE MUSCULAR DYSTROPHY | Jun 20, 2019 | Pending |
Array
(
[id] => 15993485
[patent_doc_number] => 20200172613
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-04
[patent_title] => IMMUNOLOGIC EFFECTOR CELL OF TARGETED CLD18A2, AND PREPARATION METHOD AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/448053
[patent_app_country] => US
[patent_app_date] => 2019-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8248
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16448053
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/448053 | Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof | Jun 20, 2019 | Issued |